ATA-3219

N/A

Report date: 2024/03/11 16:39:08

Base Information

Drug NameATA-3219

Drug Alias NameEBV.CD19.CAR-T (Atara Biotherapeutics)EBV.CD19.28z CAR T (Atara Biotherapeutics)EBV.CD19.CAR-T cells (Atara Biotherapeutics)ATA-3219ATA3219

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLupus Erythematosus, SystemicLupus NephritisLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAtara Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesAtara Biotherapeutics Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsLupus Erythematosus, SystemicLupus Nephritis

Other Information

ATC CodeN/A